Dyno Therapeutics is reshaping the gene therapy landscape with AI-powered AAV vectors

Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy. Using machine learning and quantitative high-throughput in vivo experimentation, we are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies.

• Industry

  • AI & Machine Learning
  • Biotechnology
  • Health + Tech

• Milestones

  • Lux investment: 2021

• Founders

  • Eric Kelsic
  • Alan Crane
  • Sam Simai
  • Adrian Veres
  • George Church
  • Tomas Bjorklund

• Latest Tweets

  • This summer Ishita Mangla, a CS student at Stanford, interned with our Machine Guided Design team. In addition to e… https://t.co/Vn7JzWse9f@Dyno_Tx - 1h
  • We're excited to attend @ChardanCM's 6th Annual Genetic Medicines Conference in NYC! Curious about how we’re rapidl… https://t.co/w1j2gleFC8@Dyno_Tx - 08:03 PM Sep 29th
  • Hear from @ekelsic how we are transforming the #genetherapy landscape with our pioneering platform approach to rapi… https://t.co/zd5TskpQCe@Dyno_Tx - 08:59 PM Sep 20th